Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
BACKGROUND
We evaluated the relationship between florbetapir-F18 positron emission tomography (FBP PET) and cerebrospinal fluid (CSF) biomarkers.


METHODS
Alzheimer's Disease Neuroimaging Initiative-Grand Opportunity and Alzheimer's Disease Neuroimaging Initiative 2 (GO/2) healthy control (HC), mild cognitive impairment (MCI), and Alzheimer's disease (AD) dementia subjects with clinical measures and CSF collected ±90 days of FBP PET data were analyzed using correlation and logistic regression.


RESULTS
In HC and MCI subjects, FBP PET anterior and posterior cingulate and composite standard uptake value ratios correlated with CSF amyloid beta (Aβ1-42) and tau/Aβ1-42 ratios. Using logistic regression, Aβ1-42, total tau (t-tau), phosphorylated tau181P (p-tau), and FBP PET composite each differentiated HC versus AD. Aβ1-42 and t-tau distinguished MCI versus AD, without additional contribution by FBP PET. Total tau and p-tau added discriminative power to FBP PET when classifying HC versus AD.


CONCLUSIONS
Based on cross-sectional diagnostic groups, both amyloid and tau measures distinguish healthy from demented subjects. Longitudinal analyses are needed.
Eli Lilly and Company, Indianapolis, IN, USA; Department of Neurology Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: hakean@lilly.com.
Ann
A
Hake
Eli Lilly and Company, Indianapolis, IN, USA; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.
Paula T
PT
Trzepacz
Eli Lilly and Company, Indianapolis, IN, USA.
Shufang
S
Wang
Eli Lilly and Company, Indianapolis, IN, USA.
Peng
P
Yu
Eli Lilly and Company, Indianapolis, IN, USA.
Michael
M
Case
Eli Lilly and Company, Indianapolis, IN, USA.
Helen
H
Hochstetler
Eli Lilly and Company, Indianapolis, IN, USA.
Michael M
MM
Witte
Eli Lilly and Company, Indianapolis, IN, USA; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana University Health Physicians Group, Indiana University Health, Indianapolis, IN, USA.
Elisabeth K
EK
Degenhardt
Eli Lilly and Company, Indianapolis, IN, USA.
Robert A
RA
Dean
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000000981:diagnostic imaging* / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D000814:Aniline Compounds / Q000378:metabolism*; D001921:Brain / Q000033:anatomy & histology / Q000000981:diagnostic imaging*; D060825:Cognitive Dysfunction / Q000134:cerebrospinal fluid / Q000000981:diagnostic imaging / Q000473:pathology; D003430:Cross-Sectional Studies; D005026:Ethylene Glycols / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D049268:Positron-Emission Tomography; D011569:Psychiatric Status Rating Scales; D012189:Retrospective Studies; D016875:tau Proteins / Q000134:cerebrospinal fluid*
D016229:Amyloid beta-Peptides; D000814:Aniline Compounds; D005026:Ethylene Glycols; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins; C545186:florbetapir
Alzheimer's Disease Neuroimaging Initiative; Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Florbetapir positron emission tomography; Mild cognitive impairment